New lung cancer combo aims to boost immune attack
NCT ID NCT07271602
Summary
This study is testing if adding a special, short-course radiation schedule to a new immunotherapy drug and standard chemotherapy can better control advanced lung cancer. It will involve about 104 adults with a specific type of lung cancer that has spread and lacks certain genetic markers. The goal is to see if this three-part combination is safe and more effective at shrinking tumors and delaying cancer growth than the current standard.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.